Literature DB >> 18046220

The natural history of pigment epithelial detachment associated with central serous chorioretinopathy.

Sachin S Mudvari1, Mitchell J Goff, Arthur D Fu, H Richard McDonald, Robert N Johnson, Everett Ai, J Michael Jumper.   

Abstract

PURPOSE: To determine the visual outcome of retinal pigment epithelial detachment (PED) associated with central serous chorioretinopathy (CSC), to further characterize the natural history of these lesions, and to provide a review of previous reports. PARTICIPANTS: Data for 340 consecutive patients with a diagnosis of CSC from January 2001 through December 2004 were retrospectively reviewed. Patients with CSC combined with angiographic evidence of PED were included in the study. MAIN OUTCOME MEASURES: Age, sex, use of corticosteroid medications, presenting visual acuity, and final visual acuity were recorded. Lesion characteristics including location, number of lesions, and laterality were recorded. Clinical outcome measures included resolution or persistence of the PED, progression to retinal pigmentary atrophy, or development of choroidal neovascularization. Fluorescein angiograms were obtained if available.
RESULTS: Thirty-four (9%) of 319 patients with angiographic evidence of CSC were diagnosed with PED over a mean follow-up of 49 months (range, 12-165 months; median, 36 months). Mean age of the patients was 47 years (range, 32-69 years; median, 48 years), most of whom were males (68%). Mean initial visual acuity was 20/32 (range, 20/13 to 20/400; median, 20/30). PEDs were commonly unilateral (88%), unifocal (76%), and extrafoveal (82%). Overall mean final visual acuity was 20/25 (range, 20/13 to 20/250; median, 20/25) for all patients. Mean visual acuity for the group of patients with subfoveal PED (18%) was 20/50 (range, 20/25 to 20/250; median, 20/50). Complete resolution of the PED occurred in 65% of patients, with resultant mean visual acuity of 20/25 (range, 20/13 to 20/250; median, 20/25). In this group, localized retinal pigment epithelial atrophy developed in 86%, with mean final visual acuity of 20/25 (range, 20/13 to 20/250; median, 20/25). Persistent PED was observed in 35% of patients, resulting in mean visual acuity of 20/25. There were no cases of choroidal neovascularization.
CONCLUSIONS: CSC with associated retinal PED may be seen and generally has a good visual prognosis. The most frequent outcome is resolution with retinal pigment epithelial atrophy. Subfoveal PED occurs less commonly and may have a poorer visual prognosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18046220     DOI: 10.1097/IAE.0b013e318156db8a

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  20 in total

1.  Subthreshold diode laser micropulse photocoagulation versus intravitreal injections of bevacizumab in the treatment of central serous chorioretinopathy.

Authors:  M J Koss; I Beger; F H Koch
Journal:  Eye (Lond)       Date:  2011-11-11       Impact factor: 3.775

2.  Full-thickness macular hole formation associated with pigment epithelial detachment: link or coincidence?

Authors:  Sunildath Cazabon
Journal:  Int Ophthalmol       Date:  2010-06-03       Impact factor: 2.031

3.  Efficacy of reduced-fluence photodynamic therapy for central serous chorioretinopathy associated with combined serous retinal detachment and fovea-involving pigment epithelial detachment.

Authors:  Serra Arf; Mumin Hocaoglu; Isil Sayman Muslubas; Murat Karacorlu
Journal:  Int Ophthalmol       Date:  2016-07-08       Impact factor: 2.031

4.  Central serous chorioretinopathy associated with rowatinex usage.

Authors:  İlknur Akyol-Salman; Deniz Leçe-Sertöz; Uğur Mumcu; Orhan Ateş; Orhan Baykal
Journal:  Eurasian J Med       Date:  2009-12

5.  Quantitative analysis of photoreceptor layer reflectivity on en-face optical coherence tomography as an estimator of cone density.

Authors:  Maher Saleh; Mathieu Flores; Anne Sophie Gauthier; Emeric Elphege; Bernard Delbosc
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-08-08       Impact factor: 3.117

6.  Long-term results of half-dose photodynamic therapy for chronic central serous chorioretinopathy with contrast sensitivity changes.

Authors:  S H Karakus; B Basarir; E Y Pinarci; E U Kirandi; A Demirok
Journal:  Eye (Lond)       Date:  2013-03-22       Impact factor: 3.775

Review 7.  Central serous chorioretinopathy: update on pathophysiology and treatment.

Authors:  Benjamin Nicholson; Jason Noble; Farzin Forooghian; Catherine Meyerle
Journal:  Surv Ophthalmol       Date:  2013 Mar-Apr       Impact factor: 6.048

8.  [Treatment of central serous chorioretinopathy: MicroPulse photocoagulation versus bevacizumab].

Authors:  I Beger; M J Koss; F Koch
Journal:  Ophthalmologe       Date:  2012-12       Impact factor: 1.059

9.  A missense variant in FGD6 confers increased risk of polypoidal choroidal vasculopathy.

Authors:  Lulin Huang; Houbin Zhang; Ching-Yu Cheng; Feng Wen; Pancy O S Tam; Peiquan Zhao; Haoyu Chen; Zheng Li; Lijia Chen; Zhengfu Tai; Kenji Yamashiro; Shaoping Deng; Xianjun Zhu; Weiqi Chen; Li Cai; Fang Lu; Yuanfeng Li; Chui-Ming G Cheung; Yi Shi; Masahiro Miyake; Yin Lin; Bo Gong; Xiaoqi Liu; Kar-Seng Sim; Jiyun Yang; Keisuke Mori; Xiongzhe Zhang; Peter D Cackett; Motokazu Tsujikawa; Kohji Nishida; Fang Hao; Shi Ma; He Lin; Jing Cheng; Ping Fei; Timothy Y Y Lai; Sibo Tang; Augustinus Laude; Satoshi Inoue; Ian Y Yeo; Yoichi Sakurada; Yu Zhou; Hiroyuki Iijima; Shigeru Honda; Chuntao Lei; Lin Zhang; Hong Zheng; Dan Jiang; Xiong Zhu; Tien-Ying Wong; Chiea-Chuen Khor; Chi-Pui Pang; Nagahisa Yoshimura; Zhenglin Yang
Journal:  Nat Genet       Date:  2016-04-18       Impact factor: 38.330

10.  Intravitreal anti-vascular endothelial growth factor combined with half-fluence photodynamic therapy for choroidal neovascularization in chronic central serous chorioretinopathy.

Authors:  E Smretschnig; S Hagen; C Glittenberg; R Ristl; I Krebs; S Binder; S Ansari-Shahrezaei
Journal:  Eye (Lond)       Date:  2016-03-11       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.